An observational study in Frontotemporal Dementia, Frontotemporal Lobar Degeneration and FTD-GRN, sponsored by The Bluefield Project to Cure Frontotemporal Dementia. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by The Bluefield Project to Cure Frontotemporal Dementia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.
Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 16th largest by enrollment of the 37 observational ones that give a count, is one of 8 that started in 2020, is one of 37 observational ones, reaches primary completion later than 17 of the 44 other live ones, and was the 64th registered.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
Browse Frontotemporal Dementia studies →31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:
Institute for Molecular Medicine · Sites in United States
Ages 65–80
Maya Henry · Sites in United States
Ages 40+
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 45+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 5 · Phase 4 3
First in 2001; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 342 is above the median of 200 across 73 observational studies indexed under Frontotemporal Dementia.
Median enrollment 60 across the 66 interventional studies, 201 across the 37 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 103 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with The Bluefield Project to Cure Frontotemporal Dementia as lead sponsor.
The Bluefield Project to Cure Frontotemporal Dementia has 1 study filed under Frontotemporal Dementia — fewer than ten, so there is no comparison to draw.
14 of the studies in Frontotemporal Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05262023Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | 2026-12 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05184569Peter Ljubenkov, MDVeri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | 2027-01-31 |
| NCT04516499The Bluefield Project to Cure Frontotemporal DementiaNeurofilament Surveillance Project (NSP) | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 103 studies in Frontotemporal Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration" (ALLFTD) study, NCT04363684. More information can be found at https://www.allftd.org/.
Frontotemporal Lobar Degeneration (FTLD), a group of clinically heterogeneous neurodegenerative diseases characterized by progressive deterioration of the frontal and temporal cortices as well as basal ganglia and brainstem structures, is a common cause of neurodegenerative dementia in people who are less than 60 years old at onset. It is uniformly fatal. FTLD is a rare disease, with an estimated prevalence of approximately 5-22 per 100,000. There are no approved treatments, however several investigational agents are in human trials and a variety of novel agents are poised to enter human development. Experience from other neurodegenerative diseases suggests that potential disease modifying treatments are most likely to be efficacious if initiated before the onset of symptoms.
Approximately 25% of FTLD cases are familial (f-FTLD) and due to autosomal dominant mutations in one of three genes: C9orf72, progranulin (GRN) or microtubule associated protein tau (MAPT). Many of the new therapies entering the clinic directly target one of these genetic causes and raise the possibility that the clinical features of FTLD could be delayed or prevented in these individuals if an efficacious therapy was initiated prior to the onset of symptoms. The major barrier to determining efficacy of novel therapeutic agents for f-FTLD in such prevention trials is the lack of an endpoint that can indicate therapeutic efficacy prior to the onset of symptoms. Our preliminary data strongly suggest that plasma neurofilament light chain (NfL) could serve as such a biomarker.
This non-interventional study is in preparation for pivotal clinical trials. Up to 335 participants will provide blood remotely via visits from traveling mobile research nurses four times a year for three years (4355 samples total) to enable the observation of peripheral NfL levels longitudinally during disease onset and progression, with the ultimate goal of qualifying plasma NfL as an endpoint for f-FTLD prevention trials. The NSP study is an ancillary study to ALLFTD, and biomarker data collected in the NSP will be correlated with ALLFTD clinical data. More information on the NSP study may be found at https://www.allftd.org/nsp.
This study is an ancillary study to ALLFTD. Thus, all NSP participants will be recruited directly from the longitudinal arm of ALLFTD.
Roughly equivalent numbers of participants will be enrolled from each of the following groups:
Although participant must be from a family with a known mutation, the participant themselves need not know their personal mutation status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
Neurofilament Light Chain Levels
To determine the longitudinal stability of plasma neurofilament light chain (NfL) measured every 3 months for 36 months in individuals at-risk for symptomatic FTLD
Time frame: 36 months
Intersubject variability of plasma NfL measurements
Concentration of plasma neurofilament light chain protein
Time frame: 36 months
Logistics measure
Participant compliance with scheduled remote blood collection and sample processing
Time frame: 36 months
Clinical and MRI correlates
To evaluate ALLFTD collected clinical and magnetic resonance imaging (MRI) neuroimaging correlates with plasma NfL levels in asymptomatic and symptomatic f-FTLD mutation carriers
Time frame: 36 months
Other biomarker evaluation
To measure other novel blood biomarkers of neurodegeneration yet to be determined
Time frame: 36 months
Plan to share: Undecided — Please consult with ALLFTD regarding individual participant data.
Started Sep 2020 (actual). Primary completion is estimated for Feb 2027, 77 months after the start.
Of 46 observational studies under Frontotemporal Dementia, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 44. This study's planned 77 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.